- Zai Lab of Shanghai is conducting a Hong Kong IPO that is expected to raise up to $845 million, offering 12.3% of the company's expanded number of shares.
- Tianjin JuveStar Biotech, a Fosun Pharma affiliate, acquired Greater China rights to an aesthetic product from Israel's Raziel Therapeutics in a $74 million agreement.
- Shanghai's I-Mab and MorphoSys AG of Munich announced they have permission to start US trials of an anti-C5aR1 antibody in patients with advanced solid tumors.
For further details see:
Week In Review: Zai Lab To Raise Up To $845 Million In Hong Kong IPO